P53 Expression and Prognosis in Lung Cancer
Author Information
Author(s): A Costa, R Silvestrini, C Mochen, C Lequaglie, P Boracchi, A Faranda, G Vessecchia, G Ravasi
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Hypothesis
Can P53 expression, DNA ploidy, and S-phase cell fraction provide prognostic information for patients with operable locally advanced non-small-cell lung cancer?
Conclusion
The study found that P53 expression, DNA ploidy, and S-phase cell fraction are not significantly related to prognosis in operable lung cancer, with pathological stage being the most important factor.
Supporting Evidence
- P53 expression was found in 55% of the tumors analyzed.
- Only pathological stage was significantly associated with relapse-free survival.
- The median follow-up time for patients was 20 months.
Takeaway
Doctors looked at certain markers in lung cancer to see if they could help predict how well patients would do, but they found that the stage of the cancer was the most important thing to consider.
Methodology
The study analyzed P53 expression, S-phase cell fraction, and DNA ploidy in tumor samples from 102 patients with operable lung cancer to assess their relationship with relapse-free survival.
Limitations
The study may have been affected by the heterogeneity of the patient population and the methods used to assess the biomarkers.
Participant Demographics
The study included 102 patients with operable stage II and IIIa non-small-cell lung cancer, consisting of 52 squamous cell carcinomas and 50 adenocarcinomas.
Statistical Information
P-Value
0.0053
Confidence Interval
(1.25-3.55)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website